Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 11/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.66 |
| ▸ | PRKACA | P17612 | 2/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401784 | 0.91 | RPS6KA5 (0.83) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL14364694 | 0.87 | RPS6KA5 (0.78) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL12676582 | 0.86 | RPS6KA5 (0.76) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6402388 | 0.83 | RPS6KA5 (0.74) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6402221 | 0.83 | RPS6KA5 (1.00) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6406324 | 0.83 | RPS6KA5 (1.00) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6400820 | 0.81 | RPS6KA5 (1.00) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6406786 | 0.80 | RPS6KA5 (0.69) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| Gw549034X SCHEMBL1900661 | 0.80 | RPS6KA5 (1.00) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B | |
| SCHEMBL6403075 | 0.79 | RPS6KA5 (1.00) | RPS6KA5ROCK1RPS6KB1PRKACAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1487441-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080125-A2 | BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | RPS6KA5 74/4885ROCK1 2/4885RPS6KB1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.